Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.73 |
| ▸ | CES1 | P23141 | 1/20 | 0.73 |
| ▸ | DAO | P14920 | 1/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.62 |
| ▸ | GSK3B | P49841 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2010106 | 0.83 | ALDH1A1 (0.66) | CES2CES1DAOKMT2AALDH1A1 | |
| SCHEMBL2008426 | 0.83 | CES2 (0.57) | CES2CES1DAOKMT2AALDH1A1 | |
| SCHEMBL71972 | 0.82 | — | — | |
| SCHEMBL29171652 | 0.81 | CES2 (0.61) | CES2CES1DAOKMT2AALDH1A1 | |
| SCHEMBL1476181 | 0.80 | — | — | |
| SCHEMBL345568 | 0.80 | — | — | |
| SCHEMBL1455897 | 0.80 | — | — | |
| SCHEMBL15891223 | 0.80 | CES2 (0.53) | CES2CES1DAOKMT2AALDH1A1 | |
| SCHEMBL8308134 | 0.80 | DAO (0.57) | CES2CES1DAOKMT2AALDH1A1 | |
| SCHEMBL15988673 | 0.78 | GSK3B (0.73) | CES2CES1DAOKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100343256-C | Biaryl substituted diazabicycloalkane amides as nicotinic acetylcholine agonists | ASTRAZENECA AB (SE) | 2007-10-17 | — | — | CN | claimed |
| CN-1678615-A | Biaryl substituted diazabicycloalkanes as nicotinic acetylcholine antagonists | ASTRAZENECA AB (SE) | 2005-10-05 | — | — | CN | claimed |
| CN-102460758-A | Semiconductor compound and device comprising the same | UNIV KENTUCKY RES FOUND | 2012-05-16 | — | — | CN | disclosed |
| CN-102209540-A | Treatment with alpha a7-selective ligands | TARGACEPT INC | 2011-10-05 | — | — | CN | disclosed |
| US-20110039841-A1 | Novel compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2011-02-17 | — | — | US | disclosed |
| EP-1763511-B1 | PHENOXYACETIC ACID DERIVATIVES AS PPAR AGONISTS | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-07-28 | — | — | EP | disclosed |
| CN-101056873-A | Carbonyl-functionalized thiophene compounds and related device structures | UNIV NORTHWESTERN (US) | 2007-10-17 | — | — | CN | disclosed |
| CN-100343256-C | Biaryl substituted diazabicycloalkane amides as nicotinic acetylcholine agonists | ASTRAZENECA AB (SE) | 2007-10-17 | — | — | CN | disclosed |
| EP-1763511-A1 | PHENOXYACETIC ACID DERIVATIVES AS PPAR AGONISTS | NOVO NORDISK A/S (DK) | 2007-03-21 | — | — | EP | disclosed |
| WO-2005105735-A1 | PHENOXYACETIC ACID DERIVATIVES AS PPAR AGONISTS | NOVO NORDISK A/S (DK) | 2005-11-10 | — | — | WO | disclosed |
| CN-1678615-A | Biaryl substituted diazabicycloalkanes as nicotinic acetylcholine antagonists | ASTRAZENECA AB (SE) | 2005-10-05 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039841-A1 | Novel compounds, their preparation and use | PPARG, PPARD, PPARA | CES2 1343/4885CES1 188/4885DAO 4142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.